ADIAL PHARMACEUTICALS, INC. Material Event: What Investors Need to Know

ADIAL PHARMACEUTICALS, INC. just made a significant move, and it's crucial for investors to understand why. This isn't merely a technical adjustment; it's a critical development with real implications for the company and its shareholders. Let's cut through the jargon and break down what you need to know.

---

1. The Core Event: A 1-for-25 Reverse Stock Split

ADIAL PHARMACEUTICALS, INC. announced a 1-for-25 reverse stock split. This means for every 25 shares of ADIAL stock you currently own, you will now hold just 1 share. While your share count decreases, the price per share theoretically increases by the same factor. For instance, if the stock traded at $0.50 per share before the split, it would theoretically trade at $12.50 per share immediately after. Your total investment value should remain the same right after the split, but remember that market dynamics can quickly change this.

The split will change the company's common stock CUSIP number to 00688A206.

2. Key Dates and Details

Here are the key dates for this corporate action:

• Stockholder Approval: Stockholders approved the reverse stock split concept on August 1, 2025.
• Board Decision: The Board of Directors later set the specific 1-for-25 ratio on February 5, 2026.
• Effective Date: The reverse stock split takes effect at 5:00 PM Eastern Time on February 5, 2026.
• Trading Commencement: ADIAL's common stock begins trading on the Nasdaq Capital Market on a split-adjusted basis under its existing ticker symbol "ADIL" at market open on February 6, 2026.

3. Why This Happened: Nasdaq Listing and Investor Perception

ADIAL PHARMACEUTICALS, a clinical-stage company developing treatments for Alcohol Use Disorder (AUD) with its lead investigational drug, AdialRx, undertakes this reverse split primarily to regain compliance with Nasdaq's minimum bid price requirement.

• The Nasdaq Mandate: Nasdaq requires listed companies to maintain a minimum bid price of at least $1.00 per share. ADIAL's stock traded significantly below this threshold for an extended period, risking delisting. Delisting severely impacts a company's reputation, liquidity, and ability to raise capital.
• Investor Appeal (The Hope): The company also hopes a higher per-share price will attract a broader range of institutional investors and potentially improve marketability. However, a reverse split alone does not change the company's underlying business fundamentals or financial health.

4. Impact and Significance: More Than Just a Number Change

This action critically preserves ADIAL's access to a major stock exchange. Staying listed on Nasdaq is vital because it:

• Boosts Credibility and Visibility: Maintains investor confidence and attracts new capital.
• Ensures Liquidity: Makes shares easily bought and sold.
• Facilitates Future Funding: Supports future equity offerings to fund clinical trials and operations.

For Investors:

• Share Count Reduction: The split will divide your total number of shares by 25.
• Fractional Shares: If your share count does not divide evenly by 25, you will not receive fractional shares. Instead, the company's transfer agent will aggregate and sell these fractional entitlements, distributing cash proceeds proportionally to affected stockholders.
• Market Value: While your immediate total dollar investment value should remain the same, the market often views reverse splits negatively. The stock price may not sustain its post-split level and could decline further, as the underlying reasons for the low pre-split price (e.g., clinical trial progress, financial performance, cash burn) may persist.

5. What Happens Next: The Road Ahead

• Immediate Effect: On February 6, 2026, your brokerage account will show fewer shares at a higher per-share price.
• Nasdaq Compliance: The immediate goal is to push and maintain the stock price above $1.00 for the required period (typically 10 consecutive business days) to regain compliance.
• Long-Term Outlook & Risks: The company explicitly states "no assurance" that the reverse split will sufficiently maintain the bid price above the minimum requirement for the necessary duration.
  • Financial Health & Strategy: A reverse split is a financial maneuver, not a cure for underlying business challenges. Investors must scrutinize ADIAL's strategy for AdialRx's clinical development (e.g., current trial phase, expected data readouts, regulatory pathway), its cash position, burn rate, and its long-term plan for achieving profitability or securing additional funding. Without a clear path to sustainable value creation, the reverse split's effect may be temporary.
  • Market Perception: Reverse splits, often associated with struggling companies, can lead to continued negative sentiment and further stock price erosion.

6. Key Takeaways for Investors

• Understand the "Why": This is primarily a defensive move to meet Nasdaq listing requirements, not a sign of fundamental business improvement.
• Monitor Post-Split Performance: Closely watch market reaction and whether the stock sustains its new price level.
• Evaluate Core Business: Focus on ADIAL's progress with AdialRx, its financial stability, and its strategy for commercialization or partnership. A reverse split does not change their drug's efficacy or operational efficiency.
• Assess Your Risk Tolerance: Reverse splits carry inherent risks, including the potential for further stock price decline. Re-evaluate your investment thesis considering this corporate action and the company's broader prospects.

This is a pivotal moment for ADIAL PHARMACEUTICALS. While it addresses an immediate listing threat, the company's long-term success will depend on its ability to advance its pipeline and demonstrate sustainable financial performance.